Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
July 18 2024 - 5:00PM
Business Wire
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision
oncology, today announced the appointment of Dr. Manuel Hidalgo
Medina to its board of directors, effective immediately. Dr.
Hidalgo currently serves as Chief of the Division of Hematology and
Medical Oncology at Weill Cornell Medicine and
NewYork-Presbyterian/Weill Cornell Medical Center.
“Dr. Hidalgo brings a wealth of expertise and leadership in
translational and clinical research, particularly in anticancer
drug development,” said Helmy Eltoukhy, chairman and co-CEO of
Guardant Health. “His extensive experience in precision oncology
and his commitment to advancing oncology care make him an
invaluable addition to our board.”
At Weill Cornell Medicine, Dr. Hidalgo oversees clinical and
translational research in hematology and medical oncology, where he
is the Walter B. Wriston Professor of Pancreatic Cancer
Research.
“With Guardant Health's innovative approaches to cancer
detection and care, I am eager to contribute to their mission of
improving patient outcomes through advanced diagnostics,” said Dr.
Hidalgo. “I look forward to collaborating with the leadership team
to accelerate the development and adoption of precision oncology
solutions.”
Dr. Hidalgo’s distinguished career includes prior roles as chief
of the Division of Hematology at Beth Israel Deaconess Medical
Center in Boston, clinical director of the Rosenberg Clinical
Cancer Center, and leadership positions at the Spanish National
Cancer Research Centre (CNIO) in Madrid and the Kimmel
Comprehensive Cancer Center. Dr. Hidalgo is also a member of the
board at Bristol Myers Squibb.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718371807/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Melissa Marasco
press@guardanthealth.com
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Jul 2023 to Jul 2024